

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 83112369.0

(51) Int. Cl.<sup>3</sup>: **A 61 K 9/06**  
**A 61 K 37/02**

(22) Date of filing: 08.12.83

(30) Priority: 10.12.82 US 448548

(43) Date of publication of application:  
27.06.84 Bulletin 84/26

(84) Designated Contracting States:  
BE CH DE FR GB IT LI LU NL SE

(71) Applicant: SYNTEX (U.S.A.) INC.  
3401 Hillview Avenue P.O. Box 10850  
Palo Alto California 94303(US)

(72) Inventor: Anik, Shabbir Tyabji  
724 Arastradero Road 313  
Palo Alto California 94306(US)

(74) Representative: Schmied-Kowarzlik, Volker, Dr. et al,  
Patentanwälte Dr. V. Schmied-Kowarzlik Dipl.-Ing. G.  
Dannenberg Dr. P. Weinhold Dr. D. Gudel Dipl.-Ing. S.  
Schubert Dr. P. Barz Siegfriedstrasse 8  
D-8000 München 40(DE)

(54) LHRH preparations for intranasal administration.

(57) The present invention relates to a novel nasal composition comprising a nona- or decapeptide having LHRH agonist or antagonist activity and a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof in a buffered aqueous solution.

5

10

-1-

LHRH PREPARATIONS FOR INTRANASAL ADMINISTRATION

15 The present invention relates to a novel LHRH formulation. More particularly, the present invention relates to an aqueous LHRH active nona- or decapeptide preparation containing a surfactant derived from a bile acid or a salt thereof which is suitable for intranasal administration.

20 Luteinizing hormone (LH) and follicular stimulating hormone (FSH) are released from the anterior pituitary gland under the control of the releasing hormone LHRH produced in the hypothalamic region. LH and FSH act on the gonads to stimulate the synthesis of steroid hormones  
25 and to stimulate gamete maturation. The pulsatile release of LHRH, and thereby the release of LH and FSH, control the reproductive cycle in domestic animals and humans. LHRH also affects the placenta, and the gonads indirectly in causing the release of chorionic  
30 gonadotropin (hCG).

LHRH peptides have heretofore been administered almost exclusively by injection. Other methods of administration, e.g., oral, nasal, intratracheal and

35

rectal administration, have been investigated but because these compounds are polypeptides, these routes of administration have had little or no pharmacological effect because of poor absorption or the effect has been somewhat uncontrollable at best because of irregular absorption. When non-injection routes are used, the drug dose must be substantially increased because the amount of drug reaching the intended site of activity is greatly reduced by mechanisms ongoing in the absorption process which prevent absorption or degrade the peptides during absorption.

The nasal administration of insulin to rats is described by S. Hirai, et al, in the International Journal of Pharmaceutics, 9, 165-172 (1981). In this reference, aqueous insulin solutions containing a surfactant have indicated that, in certain instances, the presence of certain surfactants results in decreased serum glucose levels over control solutions comprising water and insulin. The Hirai reference discloses surfactants from a broad range of types including ethers, esters, anionic surfactants, amphoterics, bile acid salts, a glycoside and a peptidelipid. Except for a few isolated cases, the polyoxyethelene fatty acid ethers, anionic, amphoteric, bile acid salt, glycoside, and peptidelipid surfactants all showed an approximately equivalent decrement in plasma glucose levels. While the decrement in plasma glucose levels is an indirect measure of insulin absorption, it is clear that most of the surfactants tested had an equal effect on the uptake of insulin administered by the nasal route in rats.

A British Patent 1,527,605 published October 4, 1978 describes the use of surfactants for enhancing insulin

uptake across the nasal membrane. Hirai is one of the inventors on this patent. The effect of sodium glycocholate on the uptake of insulin administered by nasal spray to humans is reported by A.E. Ponteroli, et al, British Medical Journal, Vol 284, pp 303-306, (1982). Since a single surfactant was used there the relative effect of sodium glycocholate versus other surfactant on insulin uptake cannot be appraised.

It has now been found that the combination of bile acids and their pharmaceutically acceptable salts with LHRH analogs greatly enhance LHRH absorption across the nasal membranes relative to other surfactants.

The present invention provides a nasal composition comprising a nona- or decapeptide or its pharmaceutically acceptable salt having LHRH agonist or antagonist activity; and a surfactant which is bile acid or a pharmaceutically acceptable salt thereof; formulated in an aqueous solution.

In one embodiment the present invention relates to a novel nasal spray composition comprising an LHRH agonist or antagonist compound plus a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof formulated in an aqueous solution which may be buffered and may contain other appropriate pharmaceutical excipients, for example, co-solvents, chelating agents, preservatives and the like.

The invention also relates to a method for enhancing the nasal uptake of a LHRH analog, which method comprises adding a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof to a nasal composition comprising a nona- or decapeptide or a pharmaceutically acceptable salt thereof having LHRH agonist or antagonist activity formulated in an aqueous solution.

Agonist and antagonist analogs of LHRH have been prepared and found to be useful in the control of fertility in both male and female; are useful in the reduction in accessory organ weight in male and female; 5 will promote weight gain in domestic animals in feedlot situations; will stimulate abortion in pregnant animals; and in general act as chemical sterilants.

The natural hormone releasing hormone, LHRH, is a decapeptide comprised of naturally occurring amino acids 10 (which have the L-configuration except for the achiral amino acid glycine). Its sequence is as follows:

(pyro)Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNH<sub>2</sub>  
                   1     2     3     4     5     6     7     8     9     10

15 A large number of analogs of this natural material have been prepared and studied in attempts to find compounds which have greater agonist or antagonist activity.

By far the most significant modification for the enhancement of agonist activity is obtained by changing 20 the 6-position residue from Gly to a D-amino acid. In addition, substantial increased agonist activity is obtained by eliminating the Gly-NH<sub>2</sub> in position 10 to afford a nonapeptide as an alkyl, cycloalkyl or fluoralkylamide or by replacing the Gly-NH<sub>2</sub> by an 25  $\alpha$ -azaglycine amide. In yet other instances modifications have been made at positions 1 and 2 in attempts to enhance agonist activity.

In addition to the preparation of agonist analogs, a number of nona- and decapeptides have been prepared which 30 are competitive antagonists to LHRH, all of which require deletion or replacement of the histidine residue at position 2. In general, it appears that a D-amino acid placed in the sequence at that position gives the best antagonist activity. It has also been shown that adding 35 a modification at the 6 position, which, without the

modification at position 2 results in the agonist activity noted above, enhances the antagonist activity of the 2-modified analogs. Additional increments in antagonist activity may be had by modifying positions 1, 5 3 and/or 10 in the already 2, 6 modified peptide. It has also been shown that N-acylation of the amino acid at position 1 is helpful.


This invention has application to LHRH and all synthetic agonist and antagonist analogs thereof. the 10 patent and periodical literature is replete with nona- and decapeptides of this type. It is intended that all such compounds will be within the scope of this invention.

Nona- or decapeptides having LHRH agonist or antagonist activity are disclosed, along with processes 15 for preparation thereof, in the following U.S. Patents. 3,813,382; 3,842,065; 3,849,389; 3,855,199; 3,886,135; 3,890,437; 3,892,723; 3,896,104; 3,901,872; 3,914,412; 3,915,947; 3,929,759; 3,937,695; 3,953,416; 3,974,135; 4,010,125; 4,018,914; 4,022,759; 4,022,760; 4,022,761; 20 4,024,248; 4,034,082; 4,072,668; 4,075,189; 4,075,192; 4,086,219; 4,101,538; 4,124,577; 4,124,578; 4,143,133; 4,234,571; 4,253,997; 4,292,313; 4,341,767.

LHRH analogs disclosed in these patents are incorporated herein by reference as if set out in full 25 herein. This list is not intended to be exhaustive of all U.S. Patents covering LHRH analogs but does represent the majority; nor is this invention limited exclusively to the compounds disclosed in the recited patents.

Of the numerous LHRH analogs disclosed by the 30 foregoing patents and in the literature in general, there are certain compounds which have been shown to be preferred for the control of fertility, enhancement or growth, treatment of prostatic cancer, for inducing abortion and other situations where LHRH agonists or 35 antagonists have utility.

One such group of agonist compound is the group of LHRH analogs disclosed in U.S. Patent No. 4,234,571 and represented by the following formula:



and the pharmaceutically acceptable salts thereof wherein:

V is tryptophyl, phenylalanyl or 3-(1-naphthyl)-L-alanyl;

10 W is tyrosyl, phenylalanyl or 3-(1-pentafluorophenyl)-L-alanyl;

X is a D-amino acid residue



wherein R is

- 20 (a) a carbocyclic aryl-containing radical selected from the group consisting of naphthyl, anthryl, fluorenyl, phenanthryl, biphenyl, benzhydryl and phenyl substituted with three or more straight chain lower alkyl groups; or
- 25 (b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenyl, perhydro-2,2-diphenylmethyl and adamantyl;

30 Y is leucyl, isoleucyl, nor-leucyl or N-methyl-leucyl; Z is glycine or -NR<sup>1</sup>, wherein R<sup>1</sup> is lower alkyl, cycloalkyl, fluoro lower alkyl or



wherein  $R^2$  is hydrogen or lower alkyl.

More preferred are those compounds of Formula I wherein V is tryptophyl or phenylalanyl; W is tyrosyl; X is 3-(2-naphthyl)-D-alanyl or 3-(2,4,6-trimethyl-phenyl)-D-alanyl; Y is leucyl or N-methyl-leucyl; and Z is glycineamide or -NH<sub>2</sub>.

Particularly preferred compounds of Formula I are:

- (pyro) Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-Leu-Arg-Pro-Gly-NH<sub>2</sub>;
- 10 (pyro) Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-N-methyl-Leu-Arg-Pro-Gly-NH<sub>2</sub>;
- (pyro) Glu-His-Phe-Ser-Tyr-3-(2-naphthyl)-D-alanyl-Leu-Arg-Pro-Gly-NH<sub>2</sub>;
- (pyro) Glu-His-Trp-Ser-Tyr-3-(2,4,6-trimethylphenyl)-D-alanyl-Leu-Arg-Pro-Gly-NH<sub>2</sub>;
- 15 (pyro) Glu-His-Trp-Ser-Tyr-3-(2-(naphthyl)-D-alanyl-Leu-Arg-Pro-NH<sub>2</sub>);
- (pyro) Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-N-methyl-Leu-Arg-Pro-NH<sub>2</sub>; and
- 20 (pyro) Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-Leu-Arg-Pro-Aza-Gly-NH<sub>2</sub>; and their pharmaceutically acceptable salts.

Further particularly preferred agonist compounds from other noted U.S. Patents and reported in the periodical literature are:


- 25 (pyro) Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-GlyNH<sub>2</sub>, Coy, C. D., J. Med. Chem., 19, 423(1976);
- (pyro) Glu-His-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-NH<sub>2</sub>, Corbin, A. & Bex, F. J., "LHRH Peptides as Female and Male Contraceptives," Shelton, J. D. & Sciarra, J. J., Eds., Harper & Row, Philadelphia (1981), pp 68-84;
- 30 (pyro) Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NH<sub>2</sub>; Rivier, J. et al, "Peptides: Chemistry, Structure and Biology - Proceedings of the Fourth
- 35



- American Peptide Symposium," R. Walter & J. Meienhofer, Eds, (1975) Ann Arbor Science Publications, p 863-870;  
 (pyro) Glu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-
- 5 Pro-GlyNH<sub>2</sub>, U.S. Patent 3,914,412;  
 (pyro) Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NH<sub>2</sub>; Fujino, M. et al, Biochem. Biophys. Res. Commun., 60, 406 (1974);  
 (pyro) Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-
- 10 Pro-GlyNH<sub>2</sub>, U.S. Patent 3,914,412;  
 (pyro) Glu-His-Trp-Ser-Tyr-D-Ser(t-But)-Leu-Arg-Pro-NH<sub>2</sub>, U.S. Pat. 4,024,248, and Konig, W., et al, "Peptides: Chemistry, Structure and Biology - Proceedings of the Fourth American Peptide Symposium," R. Walter & J. Meienhofer, Eds, (1975), Ann Arbor Science Publications,
- 15 p 883-888;  
 (pyro) Glu-His-Trp-Ser-Tyr-D-Ser(t-But)-Leu-Arg-Pro-AzaGly, Dutta, A. S., et al, Biocnem. Biophys. Res. Commun. 81, 382 (1978);
- 20 (pyro) Glu-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NH<sub>2</sub>, Vale, W. et al, "Peptides: Studies and Biological Function - Proceedings of the Sixth American Peptide Symposium," E. Gross & J. Meienhofer, Eds, Pierce Chem Co. (1979) pp 781-793;
- 25 (pyro) Glu-His-Trp-Ser-Tyr-D-pentamethyl-Phe-Leu-Arg-Pro-GlyNH<sub>2</sub>, Coy, D. H., "Clinical Neurological Endocrinology - A Pathological Physical Approach," G. Tol Ed, (1979) p 83; and  
 (pyro) Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-Leu-Arg-Pro-GlyNH<sub>2</sub>, Nestor, J., Jr. et al, J. Med. Chem., 25, 795 (1982).
- 30 Preferred antagonist analogs of LHRH are the nona- and decapeptides from U.S. Patent No. 4,341,767 and U.S. Applications Serial Nos. 387,101 filed June 10, 1982, 451,671 filed December 21, 1982, 472,692 filed March 7, 1983 and 495,226 filed May 20, 1983, and related
- 35

EPC patent application No. 83 303 343.4 (see enclosure; internal No. 23620).

Such antagonists include those of Formula (II):




and the pharmaceutically acceptable salts thereof, wherein:

10            X is N,N'-guanido-disubstituted-D-argininyl or D-homoargininyl, D-argininyl, D-lysyl, or D-alanyl residue wherein one hydrogen on C-3 of the D-alanyl is replaced by:

- a) a carbocyclic aryl-containing radical selected  
 15 from the group consisting of phenyl substituted with three or more straight chain lower alkyl or alkoxy groups, trifluoromethyl, naphthyl, anthryl, fluorenyl, phenanthryl, biphenyl and benzhydryl; or
- b) a saturated carbocyclic radical selected from  
 20 the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydro-naphthyl, perhydrobiphenyl, perhydro-2,2-diphenyl-methyl, and adamantyl; or
- c) a heterocyclic aryl containing radical selected  
 25 from the group consisting of radicals represented by the following structural formulas:

30

35



wherein A" and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine, and bromine, and G is selected from the group consisting of oxygen, nitrogen, and sulfur;

15 A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-L-prolyl, N-acyl-D-prolyl, N-acyl-D-tryptophanyl, N-acyl-D-phenylalanyl, N-acyl-D-p-halophenylalanyl, N-acyl-D,L-seryl, N-acyl-D,L-threonyl, N-acyl-glycyl, 20 N-acyl-D,L-alanyl, N-acyl-L-alkylprolyl, and N-acyl-X wherein X is as defined previously;

B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-halophenylalanyl, 2,2-diphenylglycyl, and X wherein X is as defined 25 previously;

C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl, D-phenylalanyl and X wherein X is as defined above;

30 D is an amino acyl residue selected from the group consisting of L-seryl, and D-alanyl;

Y is an amino acyl residue selected from the group consisting of L-leucyl, L-norleucyl and L-norvalyl;

35

-11-

E is D-alanyl, glycinamide or  $\text{-NH-R}^1$ , wherein  $\text{R}^1$  is lower alkyl, cycloalkyl, fluoro lower alkyl or  $\text{-NH-CO-NH-R}^2$  wherein  $\text{R}^2$  is hydrogen or lower alkyl; are disclosed.

Those embodiments of Formula II most particularly preferred are those wherein the A group N-acyl is N-Ac, especially:

5 N-Ac-Pro-D-p-F-Phe-D-Nal(2)-Ser-Tyr-D-Nal(2)-Leu-Arg-Pro-GlyNH<sub>2</sub>; and

N-Ac-Pro-D-p-Cl-Phe-D-Nal(2)-Ser-Tyr-D-Nal(2)-Leu-Arg-Pro-GlyNH<sub>2</sub>.

Also particularly preferred are the following compounds which are disclosed in the noted patent and periodical literature:

10 N-Ac- $\Delta^3$ Pro-D-p-F-Phe-D-Nal(2)-Ser-Tyr-D-Nal(2)-Leu-Arg-Pro-GlyNH<sub>2</sub>, Rivier, J., et al, "LHRH Peptides as Female and Male Contraceptives," G. I. Zatuchni, J. D. Snelton & J. J. Sciarra, Eds, Harper & Row, Philadelphia (1981), pp 13-23;

15 N-Ac- $\Delta^3$ Pro-D-p-Cl-Phe-D-Trp-Ser-Tyr-D-Trp-N-Me-Leu-Arg-Pro-GlyNH<sub>2</sub>, Rivier, J., et al, Science, 210, 93 (1980);

20 N-Ac-D-p-Cl-Phe-D-p-Cl-Phe-D-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-D-AlaNH<sub>2</sub>, Erchegyi, Peptides, 2, 251 (1981);

N-Ac-D-p-Cl-Phe-D-p-Cl-Phe-D-Trp-Ser-Tyr-D-Arg-Leu-Arg-Pro-D-AlaNH<sub>2</sub>, Coy, D. H., Endocrinology, 110, 1445 (1982); and

25 N-Ac-D-Nal(2)-D-p-F-Phe-D-Trp-Ser-Tyr-D-Arg-Leu-Arg-Pro-GlyNH<sub>2</sub>, Rivier, J., et al, Contraceptive Delivery Systems, 3, 67 (1982).

Also useful are compounds of formula II but wherein A is N-acyl- $\Delta^3$ -Pro, which can be prepared in analogous manner to the corresponding compounds of Rivier referenced above.

Such antagonists also include those of formula

A-B-C-D-E-F-G-Arg-Pro-H (III)

1 2 3 4 5 6 7 8 9 10


35 and the pharmaceutically acceptable salts thereof, wherein:

8183J


23530-FF

- A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-D,L-tryptophanyl, N-acyl-glycyl, N-Ac-D,L- $\Delta^{3,4}$ -prolyl, N-Ac-D,L-prolyl,
- 5 N-Ac-L-alkylprolyl, N-Ac-D,L-phenylalanyl, N-Ac-D,L-p-chlorophenylalanyl, N-Ac-D,L-seryl, N-Ac-D,L-threonyl, N-Ac-D,L-alanyl, 3-(1-naphthyl)-D,L-alanyl, 3-(2-naphthyl)-D,L-alanyl, 3-(2,4,6-trimethylphenyl)-D,L-alanyl,
- 10 3-(4-trifluoromethylphenyl)-D,L-alanyl, 3-(9-anthryl)-D,L-alanyl, 3-(2-fluorenyl)-D,L-alanyl, and 3-(Het)-D,L-alanyl wherein Het is a heterocyclic aryl containing radical selected from

15



and



20

wherein A'' and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine and bromine, and G is selected from the group consisting of oxygen, nitrogen and sulfur;

- 25 B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-Cl-phenylalanyl, D-p-F-phenylalanyl, D-p-nitrophenylalanyl, 3-(3,4,5-trimethoxyphenyl)-D-alanyl, 2,2-diphenylglycine, D- $\alpha$ -methyl-p-Cl-phenylalanine and
- 30 3-(2,4,6-trimethylphenyl)-D-alanyl;

- C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl, D-Me<sub>5</sub>phenylalanyl, 3-(2-pyridyl)-D-alanyl, 3-(3-pyridyl)-D-alanyl,
- 35 3-(4-pyridyl)-D-alanyl, 3-(1-naphthyl)-D-alanyl, and 3-(2-naphthyl)-D-alanyl;
- 8183J

23530-FF

D is an amino acyl residue selected from the group consisting of L-seryl, and D-alanyl;

E is an amino acyl residue selected from the group consisting of L-phenylalanyl and L-tyrosyl;

5 F is an amino acyl selected from the group consisting of the radicals represented by the following structural formulas:

a)




15 wherein

n is 1 to 5;

R<sub>1</sub> is alkyl of 1 to 12 carbon atoms, -NRR<sub>3</sub> wherein R is hydrogen or alkyl of 1 to 4 carbon atoms,

20 R<sub>3</sub> is alkyl of 1 to 12 carbon atoms, cycloalkyl, phenyl, benzyl, -(CH<sub>2</sub>)<sub>n</sub>-morpholino or -(CH<sub>2</sub>)<sub>n</sub>N(R<sub>4</sub>)<sub>2</sub> wherein n is 1 to 5 and R<sub>4</sub> is lower alkyl;


25 R<sub>2</sub> is hydrogen or R<sub>3</sub>; or R<sub>1</sub> and R<sub>2</sub> comprise a ring represented by the following structural formulas:



35



wherein  $n$  is 1 to 7;  $A$  is hydrogen, alkyl of 1 to 6 carbon atoms or cycloalkyl; and  $X$  is halo or  $A$  or

b)



10 wherein  $\text{R}_5$  is alkyl of 1 to 6 carbon atoms, benzyl, phenylethyl, cyclohexyl, cyclopentyl; and  $\text{R}_6$ ,  $\text{R}_7$  and  $\text{R}_8$  are hydrogen or alkyl of 1 to 4 carbon atoms; and  $n$  is the integer 2-5; or

c) a substituent of the formula



wherein  $\text{R}_9$  is hydrogen, alkyl of 1 to 12 carbon atoms, phenyl or phenylloweralkyl;

25  $G$  is an amino acyl residue selected from the group consisting of L-leucyl, L-norleucyl and L-norvalyl;

$H$  is D-alaninamide, D-leucinamide, glycineamide or  $-\text{NHR}_5$  wherein  $\text{R}_5$  is lower alkyl, cycloalkyl, fluoro lower alkyl, or  $\text{NHCONH-R}_{10}$  wherein  $\text{R}_{10}$  is hydrogen or  
30 lower alkyl; and the pharmaceutically acceptable salts thereof.

Preferred examples of such antagonists include:

N-Ac-D-Nal(2)-D-pCl-Phe-D-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-D-AlaNH<sub>2</sub>;

35

8183J

23530-FF

N-Ac-D-Nal(2)-D-pCl-Phe-D-Trp-Ser-Tyr-D-Deh-Leu-Arg-Pro-GlyNH<sub>2</sub>; and

5 N-Ac-D-Nal(2)-D-pF-Phe-D-Trp-Ser-Tyr-D-Deh-Leu-Arg-Pro-GlyNH<sub>2</sub> and their pharmaceutically acceptable salts, and wherein D-Deh represents the residue of the amino acid N,N'-guanido-diethyl-D-homoarginine.

The amount of peptide present in the nasal formulation will often be between 0.005 and 5 milligrams per ml of solution, particularly with agonist peptides. Preferably, with agonist peptides there will be present  
10 an amount of 0.05 to 4 milligrams per ml, but most preferably the LHRH analog will be present in an amount of 0.1 to 2.0, or 0.1 to 1.0, milligrams per ml. With antagonist peptides, often higher concentrations will be  
15 used, such as 5 to 100 mg/ml, more often 5 to 20, for example 5-10 mg/ml.

The agent which is responsible for enhancing the absorption of LHRH compounds across the nasal membrane are bile acid surfactants, and their pharmaceutically  
20 acceptable salts.

These acids are, for example, glycocholic acid, cholic acid, taurocholic acid, cholanic acid, ethocholic acid, desoxycholic acid, cnenodesoxycholic acid and dehydrocholic acid; also glycodeoxy-cholic acid. One or  
25 more acids or salts, but preferably a single pharmaceutically acceptable acid salt, is added to the aqueous solution.

The pharmaceutically acceptable surfactant salts will be any salt which retains the phenomena of enhanced peptide absorption, as well as the compound's surfactant  
30 characteristics, and which are not deleterious to the subject or otherwise contraindicated. Such salts are for example those salts derived from inorganic bases which include sodium, potassium, lithium, ammonium, calcium, magnesium, ferrous, zinc, copper, manganous, aluminum,  
35



ferric, manganic salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of

5 primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine,

10 2-dimethylaminoethanol, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine,

15 N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, tromethamine, dicyclohexylamine, choline and caffeine.

More preferably, the surfactant used in the practice

20 of this invention will be an alkali metal salt of glycocholic acid, most preferably sodium glycocholate.

The amount of surfactant used for the practice of this invention will be some amount which increases the absorption of LHRH peptides over that of other

25 surfactants which also may enhance peptide absorption to a certain degree. It has been found that such an amount is often in the range between 0.2 and 15%, more often 0.2 to 5 percent by weight/volume of the solution. It is preferred that the surfactant be present in an amount

30 between about 0.5 to 4 percent by weight volume, conveniently about 1 percent by weight volume, preferably about 2 percent by weight volume.

The subject nasal formulations will be formulated in water but more preferably it will be formulated in a

35 solution buffered to a pH of between about 3.0 and 8.0,

most preferably pH 5.0 - 5.4, by means of some pharmaceutically acceptable buffer system. Any pharmaceutically acceptable buffering system capable of maintaining a pH in the denoted range may be used for the practice of this invention. A typical buffer will be, for example, an acetate buffer, a phosphate buffer, a citrate buffer, a succinate buffer or the like. The buffer of choice herein is an acetate buffer in a concentration of between 0.005 and 0.1 molar, most preferably 0.02 molar. Water or buffer solution is added in a quantity sufficient to make volume.

Other materials such as preservatives, salts to achieve the tonic value of tissue, or other additives indicated by known nasal formulation chemistry may be added to these formulations. Particularly advantageous other such materials include surfactants, suitably non-ionic surfactants such as the polysorbates, in concentrations suitably in the range 0.1 to 5, more suitably 0.25 to 2% weight volume.

It has been found that often to obtain enhanced solubility and stability, the molar ratio of bile acid to peptide is usefully  $\geq 20:1$ , such as  $\geq 25:1$ .

In one suitable embodiment, the present invention relates to a nasal spray composition having enhanced LHRH polypeptide absorption comprising 0.005 to 5mg/ml of a nona- or decapeptide or its pharmaceutically acceptable salt having LHRH agonist or antagonist activity; 0.2 to 5% by weight/volume of a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof; and a buffered aqueous solution in a quantity sufficient to make volume.

In a further suitable embodiment, this invention also relates to a method for the nasal uptake of LHRH which method comprises adding 0.2 to 5 percent by

weight/volume of a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof to a nasal spray composition comprising 0.005 to 5 mg/ml of a nona- or decapeptide or its pharmaceutically acceptable salt  
5 having LHRH agonist or antagonist activity; and buffered aqueous solution in a quantity sufficient to make volume.

The invention also provides a process for preparing the nasal compositions of the invention, which comprises bringing into aqueous solution the peptide and the  
10 surfactant. As will be clear from the foregoing, this process may be carried out in known manner for preparing nasal aqueous compositions. Suitably, the peptide is first dissolved in buffer, and then added to the surfactant, the pH adjusted as required, and the volume  
15 made up to the desired level. Additional components can be added in at any convenient stage in the process.

The nasal compositions of this invention may be administered in conventional manner. For example, sufficient composition to deliver an effective dose of  
20 LHRH analog is administered to the nostrils, conveniently in a divided dose being administered to each nostril, suitably by means of a spray. Suitably a spray bottle with a metered dose (conveniently 100  $\mu$ l per spray) spray attachment is used.

25 The invention is illustrated by the following nonlimiting examples.

#### EXAMPLE 1

6.25 milligrams of (pyro)Glu-His-Trp-Ser-Tyr-  
30 3-(2-naphthyl)-D-alanyl-Leu-Arg-Pro-Gly-NH<sub>2</sub> were dissolved in 5 ml of a 0.02 molar acetate buffer solution having a pH of about 5.2 in a volumetric flask. A hundred milligrams of sodium glycocholate were then dissolved in this solution which is brought almost to

35

volume, the pH adjusted to 5.2 plus or minus 0.2 and then a volume of buffer added in a quantity sufficient to make 10 ml.

5

EXAMPLE 2

1 mg of (pyro) Glu-His-Trp-Ser-Tyr-3- (2-naphthyl)-D-alanyl-Leu-Arg-Pro-Gly-NH<sub>2</sub> was dissolved in 50 ml of a 0.02 molar acetate buffer solution having a pH of about 5.2, and was added to a solution containing 500 mg of sodium glycocholate, the pH adjusted to 5.2 ± 0.2, and then a volume of buffer added in a quantity sufficient to make 100 ml.

10

EXAMPLE 3

2 mg of (pyro) Glu-His-Trp-Ser-Tyr-3- (2-naphthyl)-D-analyl-Leu-Arg-Pro-Gly-NH<sub>2</sub> was dissolved in 5 ml of a 0.02 molar phosphate buffer having a pH of about 7.0, and was added to a solution containing 75 mg of sodium glycodeoxy-cholate, the pH adjusted to 7.0 ± 0.2, and then a volume of buffer added in a quantity sufficient to make 10 ml.

15

20

EXAMPLE 4

50 mg of N-Ac-D-Nal(2)-D-pCl-Phe-D-Trp-Ser-Tyr-D-Deh-Leu-Arg-Pro-D-AlaNH<sub>2</sub> was dissolved in 5 ml of a 0.02 molar acetate buffer solution having a pH of about 5.2, and was added to a solution containing 500 mg of sodium glycocholate, the pH adjusted to 5.2 ± 0.2, and then a volume of buffer added in a quantity sufficient to make 10 ml.

25

30

EXAMPLE 5

The procedure of Example 2 was repeated, but using 17.5 mg of peptide and 200 mg of sodium glycocholate.

35

EXAMPLE 6

The procedure of Example 2 was repeated, but using 12.5 mg of peptide and 200 mg of sodium glycocholate.

5

EXAMPLE 7

The procedure of Example 2 was repeated, but 0.5% (w/v) of Polysorbate 20 (polyoxyethylene 20 sorbitan monolaurate) was also incorporated in the solution.

10

EXAMPLE 8

The procedure of Example 2 was repeated, but using 10 mg of peptide and 150 mg of sodium glycocholate.

Note, in the Examples the peptides were used in the form of their acetate salts.

BIOLOGICAL DATA

The enhancement of absorption of (pyro)Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-Leu-Arg-Pro-Gly-NH<sub>2</sub> by sodium glycocholate is illustrated in the following Table I.

25

30

35

TABLE 1

5	FORMULATION	DRUG CONC	AVG DOSE	PEAK PLASMA	AUC
		MG/ML	PER MONKEY	LEVEL	(8 HRS)
			UG	NG/ML	
	STANDARD NASAL	0.625	133	0.23 (0.08)	0.63
10	+1% SODIUM GLYCOCHOLATE	0.625	120	11.1 (2.13)	14.1
	SUBCUTANEOUS		5	1.9 (0.35)	5.5

[Numbers in parenthesis are standard error. Standard nasal formulation is the peptide dissolved in acetate buffer, and at the same pH as the test formulation, but not including the sodium glycocholate.]

Further absorption tests were carried out in monkeys, as reported below in Table 2:

TABLE 2

20	FORMULATION	DRUG CONC	AVG DOSE	PEAK PLASMA	AUC
		MG/ML	PER MONKEY	LEVEL	(8 HRS)
			UG	NG/ML	
25	STANDARD NASAL	1.25	272	1.84	4.6
	+2% SODIUM GLYCOCHOLATE	1.25	243	26.4	38.3
30	+1% SODIUM GLYCOCHOLATE AND 0.5% POLYSORBATE	0.625	123	5.5	

NASAL TOXICITY

The composition of Example 5 was administered to Beagle dogs intranasally at a dose of 0.4 ml per dog per day for 28 days. The nasal cavities of the dogs were  
5 examined, and no changes attributable to the composition were observed.

10

15

20

25

30


35

8183J

23530-FF

CLAIMS:

1. A nasal composition comprising a nona- or decapeptide or its pharmaceutically acceptable salt  
5 having LHRH agonist or antagonist activity; and a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof; formulated in an aqueous solution.
- 10 2. A composition according to Claim 1 which is a nasal spray composition comprising 0.005 to 5 mg/ml of a nona- or decapeptide or its pharmaceutically acceptable salt having LHRH agonist or antagonist activity; 0.2 to 5  
15 percent by weight/volume of a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof; and buffered aqueous solution in a quantity sufficient to make volume.
- 20 3. A composition according to Claim 2 wherein the LHRH compound is an agonist represented by the formula




and the pharmaceutically acceptable salts thereof wherein:

25 V is tryptophyl, phenylalanyl or 3-(1-naphthyl)-L-alanyl;

W is tyrosyl, phenylalanyl or 3-(1-pentafluorophenyl)-L-alanyl;

X is a D-amino acid residue

30



35




wherein R is

- (a) a carbocyclic aryl-containing radical selected from the group consisting of naphthyl, anthryl, fluorenyl, phenanthryl, biphenyl, benzhydryl and phenyl substituted with three or more straight chain lower alkyl groups; or
- (b) a saturated carbocyclic radical selected from the group consisting of cyclonexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenyl, perhydro-2,2-diphenylmethyl and adamantyl;

Y is leucyl, isoleucyl, nor-leucyl or N-methyl-leucyl;

Z is glycinamide or  $-NR-R^1$ , wherein

$R^1$  is lower alkyl, cycloalkyl, fluoro lower alkyl or




wherein  $R^2$  is hydrogen or lower alkyl and the surfactant is an alkali metal salt of a bile acid.

4. A composition according to Claim 3 wherein said compound is (pyro)Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-Leu-Arg-Pro-Gly-NH<sub>2</sub> or a pharmaceutically acceptable salt thereof.

5. A composition according to Claim 4, wherein the peptide is present in an amount of 0.05 to 4 milligrams/ml and said surfactant is sodium glycocholate which is present in an amount of 0.5 to 4 percent weight/volume.

6. A composition according to Claim 1 wherein said compound is an antagonist having the formula



and the pharmaceutically acceptable salts thereof, wherein:

X is N,N'-guanido-disubstituted-D-argininyl or 10 D-homoargininyl, D-argininyl, D-lysyl, or D-alanyl residue wherein one hydrogen on C-3 of the D-alanyl is replaced by:


a) a carbocyclic aryl-containing radical selected from the group consisting of phenyl substituted with 15 three or more straight chain lower alkyl or alkoxy groups, trifluoromethyl, naphthyl, anthryl, fluorenyl, phenanthryl, biphenyl and benzhydryl; or

b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three 20 or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenyl, perhydro-2,2-diphenylmethyl, and adamantyl; or

c) a heterocyclic aryl containing radical selected from the group consisting of radicals represented by the 25 following structural formulas:

30

35



wherein A'' and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine, and bromine, and G is selected from the group consisting of oxygen, nitrogen, and sulfur;

15 A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-L-prolyl, N-acyl-D-prolyl, N-acyl-D-tryptophanyl, N-acyl-D-phenylalanyl, N-acyl-D-p-halophenylalanyl, N-acyl-D,L-seryl, N-acyl-D,L-threonyl, N-acyl-glycyl, 20 N-acyl-D,L-alanyl, N-acyl-L-alkylprolyl, and N-acyl-X wherein X is as defined previously;

25 B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-halophenylalanyl, 2,2-diphenylglycyl, and X wherein X is as defined previously;


C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl, D-phenylalanyl and X wherein X is as defined above;

30 D is an amino acyl residue selected from the group consisting of L-seryl, and D-alanyl;

Y is an amino acyl residue selected from the group consisting of L-leucyl, L-norleucyl and L-norvalyl;


35

5        7. A composition according to Claim 1, wherein  
said compound is an antagonist having the formula




and the pharmaceutically acceptable salts thereof,  
wherein:

A is an amino acyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-D,L-tryptophanyl, N-acyl-glycyl, N-Ac-D,L- $\Delta^{3,4}$ -prolyl, N-Ac-D,L-prolyl, N-Ac-L-alkylprolyl, N-Ac-D,L-phenylalanyl, N-Ac-D,L-p-chlorophenylalanyl, N-Ac-D,L-seryl, N-Ac-D,L-threonyl, N-Ac-D,L-alanyl, 3-(1-naphthyl)-D,L-alanyl, 3-(2-naphthyl)-D,L-alanyl, 3-(2,4,6-trimethylphenyl)-D,L-alanyl, 3-(4-trifluoromethylphenyl)-D,L-alanyl, 3-(9-anthryl)-D,L-alanyl, 3-(2-fluorenyl)-D,L-alanyl, and 3-(Het)-D,L-alanyl wherein Het is a heterocyclic aryl containing radical selected from



and



wherein A" and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine and 35 bromine, and G is selected from the group consisting of oxygen, nitrogen and sulfur;

B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-Cl-phenylalanyl, D-p-F-phenylalanyl, D-p-nitrophenylalanyl, 3-(3,4,5-trimethoxyphenyl)-D-alanyl, 2,2-diphenylglycine, 5 D- $\alpha$ -methyl-p-Cl-phenylalanine and 3-(2,4,6-trimethylphenyl)-D-alanyl;


C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl, D-Me<sub>5</sub>phenylalanyl, 10 3-(2-pyridyl)-D-alanyl, 3-(3-pyridyl)-D-alanyl, 3-(4-pyridyl)-D-alanyl, 3-(1-naphthyl)-D-alanyl, and 3-(2-naphthyl)-D-alanyl;

D is an amino acyl residue selected from the group consisting of L-seryl, and D-alanyl;

15 E is an amino acyl residue selected from the group consisting of L-phenylalanyl and L-tyrosyl;

F is an amino acyl selected from the group consisting of the radicals represented by the following structural formulas:

20 a)




wherein

n is 1 to 5;


30 R<sub>1</sub> is alkyl of 1 to 12 carbon atoms, -NRR<sub>3</sub> wherein R is hydrogen or alkyl of 1 to 4 carbon atoms, R<sub>3</sub> is alkyl of 1 to 12 carbon atoms, cycloalkyl, phenyl, benzyl, -(CH<sub>2</sub>)<sub>n</sub>-morpholino or -(CH<sub>2</sub>)<sub>n</sub>N(R<sub>4</sub>)<sub>2</sub> wherein n is 1 to 5 and R<sub>4</sub> is lower alkyl;

35

$R_2$  is hydrogen or  $R_3$ ; or  $R_1$  and  $R_2$  comprise a ring represented by the following structural formulas:




wherein  $n$  is 1 to 7;  $A$  is hydrogen, alkyl of 1 to 6 carbon atoms or cycloalkyl; and  $X$  is halo or  $A$  or  
b)



20 wherein  $R_5$  is alkyl of 1 to 6 carbon atoms, benzyl, phenylethyl, cyclohexyl, cyclopentyl; and  $R_6$ ,  $R_7$  and  $R_8$  are hydrogen or alkyl of 1 to 4 carbon atoms; and  $n$  is the integer 2-5; or

25 c) a substituent of the formula



35 wherein  $R_9$  is hydrogen, alkyl of 1 to 12 carbon atoms, phenyl or phenylloweralkyl;

G is an amino acyl residue selected from the group consisting of L-leucyl, L-norleucyl and L-norvalyl;

H is D-alaninamide, D-leucinamide, glycineamide or  $\text{-NHR}_5$  wherein  $\text{R}_5$  is lower alkyl, cycloalkyl, fluoro lower alkyl, or  $\text{NHCONH-R}_{10}$  wherein  $\text{R}_{10}$  is hydrogen or lower alkyl; and the pharmaceutically acceptable salts thereof.

8. A composition according to Claim 7, wherein the compound is N-Ac-D-Nal(2)-D-pCl-Phe-D-Trp-Ser-Tyr-D-Deh-Leu-Arg-Pro-D-AlaNH<sub>2</sub> or a pharmaceutically acceptable salt thereof.

9. A composition according to any one of the preceding claims, also including an additional surfactant.

10. A composition according to any one of the preceding claims, wherein the molar ratio of bile acid to peptide is  $\geq 20:1$ .

11. A method for enhancing the nasal uptake of a LHRH analog, which method comprises adding a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof to a nasal composition comprising a nona- or decapeptide or a pharmaceutically acceptable salt thereof having LHRH agonist or antagonist activity formulated in an aqueous solution.

12. A method according to Claim 11 which method comprises adding 0.2 to 5 percent by weight/volume of a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof to a nasal spray composition comprising 0.005 to 5 mg/ml of a nona- or decapeptide or its pharmaceutically acceptable salt having LHRH agonist or antagonist activity; and buffered aqueous solution in a quantity sufficient to make volume.

13. A process for preparing a composition according to Claim 1, which comprises bringing into aqueous solution the peptide and the surfactant.

5

10

15

20

25

30

35

8183J

23530-FF





European Patent  
Office

# EUROPEAN SEARCH REPORT

0111841

Application number

EP 83 11 2369

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
X, Y	GB-A-1 454 105 (HOECHST AG) * Page 1, lines 29-57; page 2, line 111 - page 3, line 36; page 5, line 51 - page 7, line 98 *	1-13	A 61 K 9/06 A 61 K 37/02
Y, D	FR-A-2 321 275 (TAKEDA CHEMICAL INDUSTRIES, LTD.) * Page 12, lines 24-27, claim 7 *	1-13	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12-03-1984	Examiner BRINKMANN C.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**